Abstract: A hemodialysis machine comprising a dialysate flow path for delivering a flow of dialysate solution through a dialyser, the flow path including a flow balancer for achieving a balance in the dialysate solution flow volume observed between an inlet and an outlet of the dialyser over the course of a treatment, the flow balancer comprising a first flow balance pump having an inlet valve and an outlet valve and a second flow balance pump having an inlet valve and an outlet valve, wherein the flow path further includes a flow restrictor means downstream of the flow balance pumps to reduce the pressure difference across the valves in the dialysate flow path.

Abstract: A hemodialysis machine comprising a dialysate flow path for delivering a flow of dialysate solution through a dialyser, the flow path including a flow balancer for achieving a balance in the dialysate solution flow volume observed between an inlet and an outlet of the dialyser over the course of a treatment, the flow balancer comprising a first flow balance pump having an inlet valve and an outlet valve and a second flow balance pump having an inlet valve and an outlet valve, wherein the flow path further includes a flow restrictor means downstream of the flow balance pumps to reduce the pressure difference across the valves in the dialysate flow path.

Abstract: The present invention relates to antibodies to novel members of the Tumor Necrosis Factor (TNF) receptor family called TR2 receptor and their uses in pathological conditions. Hybridoma cell lines producing such mAbs, methods of in vivo imaging of pathological conditions, and methods of treating and diagnosing pathological conditions, caused by abnormal functioning, production or metabolism of TR2 receptors are also provided. In vitro assays for detecting the presence of TR2 and for evaluating the binding affinity of a test compound are also described.